Emerging targets for anticancer vaccination: PD-1.

Tobias, J; Steinberger, P; Drinic, M; Wiedermann, U

Tobias, J; Steinberger, P; Drinic, M; Wiedermann, U.

Afiliação

Tobias J; Institute of Specific Prophylaxis and Tropical Medicine, Center for Pathophysiology, Infectiology and Immunology, Medical University of Vienna, Vienna, Austria. Electronic address: joshua.tobias@meduniwien.ac.at.
Steinberger P; Division of Immune Receptors and T Cell Activation, Institute of Immunology, Center for Pathophysiology, Infectiology and Immunology, Medical University of Vienna, Vienna, Austria.
Drinic M; Institute of Specific Prophylaxis and Tropical Medicine, Center for Pathophysiology, Infectiology and Immunology, Medical University of Vienna, Vienna, Austria.
Wiedermann U; Institute of Specific Prophylaxis and Tropical Medicine, Center for Pathophysiology, Infectiology and Immunology, Medical University of Vienna, Vienna, Austria. Electronic address: ursula.wiedermann@meduniwien.ac.at.

ESMO Open ; 6(5): 100278, 2021 10.

Article em En | MEDLINE | ID: mdl-34649221

Assuntos

Antineoplásicos Imunológicos; Vacinas Anticâncer; Neoplasias; Receptor de Morte Celular Programada 1; Anticorpos Monoclonais/farmacologia; Antineoplásicos Imunológicos/farmacologia; Humanos; Neoplasias/tratamento farmacológico; Receptor de Morte Celular Programada 1/antagonistas & inibidores; Vacinação

Palavras-chave

PD-1; immune checkpoint inhibitors; mimotopes/peptides; small molecules; vaccination

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Contexto em Saúde: 2_ODS3 Base de dados: MEDLINE Assunto principal: Vacinas Anticâncer / Receptor de Morte Celular Programada 1 / Antineoplásicos Imunológicos / Neoplasias Limite: Humans Idioma: En Revista: ESMO Open Ano de publicação: 2021 Tipo de documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google